Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial-Reference-Cited by-同舟云学术

Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial

Published:2017-02-09 Issue:3 Volume:7 Page:e00628
ISSN:2162-3279
Container-title:Brain and Behavior
language:en
Short-container-title:Brain Behav

Author:

Katz David A.¹,Locke Charles¹,Greco Nicholas¹,Liu Wei¹,Tracy Katherine A.¹

Affiliation:

1. AbbVie Inc.; North Chicago IL USA

Publisher

Wiley

Subject

Behavioral Neuroscience

Reference20 articles.

1. Do venlafaxine XR and paroxetine equally influence negative and positive affect?;Dichter;Journal of Affective Disorders,2005

2. Anatomy of melancholia: Focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin;Dinan;Journal of Anatomy,2005

3. Ten-year trends in quality of care and spending for depression: 1996 through 2005;Fullerton;Archives of General Psychiatry,2011

4. Antidepressant- and anxiolytic-like effects of the vasopressin V1B antagonists ABT-436 and ABT-558;Gaalen;Proceedings of Society for Neuroscience, Washington DC, USA,2008

5. Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436;Katz;Psychopharmacology (Berl),2016

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point;Pharmacopsychiatry;2024-08-19

2. Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention;Psychiatry and Clinical Neurosciences;2024-06-25

3. The HPA Axis as Target for Depression;Current Neuropharmacology;2024-05

4. Therapeutic potential of vasopressin in the treatment of neurological disorders;Peptides;2024-04

5. Vasopressin as Possible Treatment Option in Autism Spectrum Disorder;Biomedicines;2023-09-22